Pierre Fabre Group

Pierre Fabre is the 2nd largest dermo-cosmetics laboratory in the world and the 2nd largest private French pharmaceutical group. In 2017, it generated 2,318 million euros in net sales, of which 62% came from its international business and 62% from its dermo-cosmetics division. Pierre Fabre, which has always been headquartered in the South-West of France, owns subsidiaries in 43 countries, enjoys distribution agreements in over 130 countries and counts around 13,500 employees worldwide. Pierre Fabre’s portfolio represents a continuum of activities spanning from prescription drugs and consumer health care products to dermo-cosmetics. In 2017, Pierre Fabre dedicated almost 143 million euros to R&D, shared between oncology, dermatology, the central nervous system, consumer health care and dermo-cosmetics.

Related News

CANNABIS INDUSTRY GIANT WAYOFLEAF.COM EXPANDS HEALTH-SPECIFIC CONTENT, INTRODUCES MEDICAL REVIEW TEAM

Prnewswire | September 30, 2020

news image

In a bid to improve the quality and availability of information on health-specific cannabis use, industry giant WayofLeaf.com has introduced a team of doctors and health experts to review thousands of topics relating to the use of medical cannabis and CBD for specific health conditions. The website, which for years has provided a reliable informational resource for medical cannabis patients, believes it is time for cannabis users of all types to have access to trustworthy, research-backed conten...

Read More

SMALL TACTICS TO COUNTER BIG PHARMA’S INFLUENCE ON MEDICATION OVERLOAD

STAT | January 28, 2020

news image

Money talks in Washington, D.C., and no sector of the economy speaks more loudly than the pharmaceutical and biotech industry. Its flow of cash has fostered an epidemic of medication overload. Over the past five years, pharma has spent about $1.2 billion lobbying federal lawmakers, far more than any other industry. The industry has massive influence over public policy, much of it devoted in recent months to hindering legislative efforts to lower drug prices. In addition to keeping prices high, t...

Read More

BUSINESS INSIGHTS

SUVODA AND N-SIDE ANNOUNCE AGREEMENT TO DELIVER INTEGRATED CLINICAL TRIAL OPTIMIZATION AND IRT SOLUTIONS FOR REAL-TIME DEMAND PLANNING

Suvoda LLC | May 13, 2022

news image

Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas such as oncology, central nervous system, and rare disease, today announced they have entered into an agreement to partner with N-SIDE — a deeptech company that empowers organizations in the clinical trials industry to make better decisions and optimize the use of critical resources.  To date, the two companies have successfully partnered on more than 100 clinical ...

Read More

PHARMA TECH

AMERISOURCEBERGEN PARTNERS WITH CHRONICLED TO OPTIMIZE PHARMACEUTICAL CHARGEBACK ACCURACY USING BLOCKCHAIN-POWERED TECHNOLOGY

AmerisourceBergen | April 22, 2022

news image

Global healthcare company AmerisourceBergen announced its partnership with Chronicled, the administrator of the MediLedger Network, to leverage a new blockchain-powered solution designed to enhance pharmaceutical chargeback accuracy and significantly reduce chargeback rejections. The blockchain solution will allow AB to streamline and optimize the complex process of pharmaceutical chargebacks while creating greater connectivity for its suppliers and customers. Over the past three years, AB has c...

Read More
news image

CANNABIS INDUSTRY GIANT WAYOFLEAF.COM EXPANDS HEALTH-SPECIFIC CONTENT, INTRODUCES MEDICAL REVIEW TEAM

Prnewswire | September 30, 2020

In a bid to improve the quality and availability of information on health-specific cannabis use, industry giant WayofLeaf.com has introduced a team of doctors and health experts to review thousands of topics relating to the use of medical cannabis and CBD for specific health conditions. The website, which for years has provided a reliable informational resource for medical cannabis patients, believes it is time for cannabis users of all types to have access to trustworthy, research-backed conten...

Read More
news image

SMALL TACTICS TO COUNTER BIG PHARMA’S INFLUENCE ON MEDICATION OVERLOAD

STAT | January 28, 2020

Money talks in Washington, D.C., and no sector of the economy speaks more loudly than the pharmaceutical and biotech industry. Its flow of cash has fostered an epidemic of medication overload. Over the past five years, pharma has spent about $1.2 billion lobbying federal lawmakers, far more than any other industry. The industry has massive influence over public policy, much of it devoted in recent months to hindering legislative efforts to lower drug prices. In addition to keeping prices high, t...

Read More
news image

BUSINESS INSIGHTS

SUVODA AND N-SIDE ANNOUNCE AGREEMENT TO DELIVER INTEGRATED CLINICAL TRIAL OPTIMIZATION AND IRT SOLUTIONS FOR REAL-TIME DEMAND PLANNING

Suvoda LLC | May 13, 2022

Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas such as oncology, central nervous system, and rare disease, today announced they have entered into an agreement to partner with N-SIDE — a deeptech company that empowers organizations in the clinical trials industry to make better decisions and optimize the use of critical resources.  To date, the two companies have successfully partnered on more than 100 clinical ...

Read More
news image

PHARMA TECH

AMERISOURCEBERGEN PARTNERS WITH CHRONICLED TO OPTIMIZE PHARMACEUTICAL CHARGEBACK ACCURACY USING BLOCKCHAIN-POWERED TECHNOLOGY

AmerisourceBergen | April 22, 2022

Global healthcare company AmerisourceBergen announced its partnership with Chronicled, the administrator of the MediLedger Network, to leverage a new blockchain-powered solution designed to enhance pharmaceutical chargeback accuracy and significantly reduce chargeback rejections. The blockchain solution will allow AB to streamline and optimize the complex process of pharmaceutical chargebacks while creating greater connectivity for its suppliers and customers. Over the past three years, AB has c...

Read More